NDAORALTABLETPriority Review
Approved
Feb 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
PYRIDOSTIGMINE BROMIDE (pyridostigmine bromide) by Medica Corp is inhibitor. First approved in 2003.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pyridostigmine bromide is an oral acetylcholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction. It is primarily indicated for myasthenia gravis and other conditions involving neuromuscular transmission defects. The drug works by inhibiting the breakdown of acetylcholine, thereby enhancing muscular strength and function.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team contraction or redeployment initiatives.
Mechanism of Action
inhibitor.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on pyridostigmine bromide offers experience in managing a mature, stable specialty pharmaceutical product in a niche indication. Career growth may be limited by LOE proximity, making this role best suited for professionals seeking to deepen expertise in neuromuscular disorders or transition to post-LOE commercialization strategies.
Brand ManagerField Sales Representative
Worked on PYRIDOSTIGMINE BROMIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.